NEW YORK (GenomeWeb) – As part of its effort to focus on its molecular diagnostics business, PDI announced today that it has agreed to sell off its biomedical commercialization and marketing services business to Publicis Group for up to roughly $48 million.

PDI also said it will assume the name of its molecular diagnostics subsidiary, Interpace Diagnostics, and chance its Nasdaq trading symbol to IDXG. The sale is expected to close in the fourth quarter.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers have sequenced the northern white rhinoceros to gauge whether it could be brought back from the edge of extinction, the New York Times reports.

Bavaria expands its forensic genetic analyses to include DNA phenotyping, raising discrimination concerns.

Tufts University researchers found a role for miRNA in transmitting stress between generations, the Economist reports.

In Science this week: gut microbiome influences liver cancer growth, spread; and more.